Literature DB >> 29169525

Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.

Yoko Nakanishi1, Shinobu Masuda1, Yuko Iida2, Noriaki Takahashi3, Shu Hashimoto2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29169525     DOI： 10.1016/j.jtho.2017.08.009

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  10 in total

1.  Salivary Intraductal Carcinoma Arising within Intraparotid Lymph Node: A Report of 4 Cases with Identification of a Novel STRN-ALK Fusion.

Authors:  Lisa M Rooper; Lester D R Thompson; Jeffrey Gagan; Bahram R Oliai; Ilan Weinreb; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2020-07-13

2.  Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.

Authors:  Caroline E McCoach; Collin M Blakely; Kimberly C Banks; Benjamin Levy; Ben M Chue; Victoria M Raymond; Anh T Le; Christine E Lee; Joseph Diaz; Saiama N Waqar; William T Purcell; Dara L Aisner; Kurtis D Davies; Richard B Lanman; Alice T Shaw; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2018-03-29       Impact factor: 12.531

3.  Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.

Authors:  Caroline E McCoach; Anh T Le; Katherine Gowan; Kenneth Jones; Laura Schubert; Andrea Doak; Adriana Estrada-Bernal; Kurtis D Davies; Daniel T Merrick; Paul A Bunn; W Tom Purcell; Rafal Dziadziuszko; Marileila Varella-Garcia; Dara L Aisner; D Ross Camidge; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2018-04-10       Impact factor: 12.531

Review 4.  Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces.

Authors:  Hao Huang
Journal:  Int J Mol Sci       Date:  2018-11-02       Impact factor: 5.923

5.  Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report.

Authors:  Diego Enrico; Ludovic Lacroix; Jeanne Chen; Etienne Rouleau; Jean-Yves Scoazec; Yohann Loriot; Lambros Tselikas; Cécile Jovelet; David Planchard; Anas Gazzah; Laura Mezquita; Maud Ngo-Camus; Stefan Michiels; Christophe Massard; Gonzalo Recondo; Francesco Facchinetti; Jordi Remon; Jean-Charles Soria; Fabrice André; Gilles Vassal; Luc Friboulet; Benjamin Besse
Journal:  JTO Clin Res Rep       Date:  2020-03-07

Review 6.  Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.

Authors:  Mengnan Li; Zhou An; Qiusu Tang; Yutong Ma; Junrong Yan; Songan Chen; Yina Wang
Journal:  J Cell Mol Med       Date:  2021-09-19       Impact factor: 5.310

7.  Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report.

Authors:  Kunyan Sun; Ligong Nie; Lin Nong; Yuan Cheng
Journal:  Thorac Cancer       Date:  2021-05-07       Impact factor: 3.500

8.  Combined use of salivary biomarkers and carcinoembryonic antigen for lung cancer detection in a Chinese population.

Authors:  Xi Shang; Huanpu Zi; Yangyang Li; Yu Gao; Changsheng Ge; Zhongmei Sun; Youmin Zhang
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

9.  STRN-ALK Fusion-Positive Case of Breast Cancer With Response to Alectinib.

Authors:  Andrew D Kelly; Tom Wiklund; Juha Kononen; James Creeden
Journal:  JCO Precis Oncol       Date:  2021-08-11

10.  Combined use of circulating tumor cells and salivary mRNA to detect non-small-cell lung cancer.

Authors:  Xianwen Gu; Junfeng He; Guanglei Ji
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.